These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 21999631)
1. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Dejesus E; Mills A; Bhatti L; Conner C; Storfer S Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631 [TBL] [Abstract][Full Text] [Related]
2. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L; Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816 [TBL] [Abstract][Full Text] [Related]
3. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). Podzamczer D; Andrade-Villanueva J; Clotet B; Taylor S; Rockstroh JK; Reiss P; Domingo P; Gellermann HJ; de Rossi L; Cairns V; Soriano V HIV Med; 2011 Jul; 12(6):374-82. PubMed ID: 21518220 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. Vrouenraets SM; Wit FW; Fernandez Garcia E; Moyle GJ; Jackson AG; Allavena C; Raffi F; Jayaweera DT; Mauss S; Katlama C; Fisher M; Slama L; Hardy WD; Dejesus E; van Eeden A; Reiss P; HIV Med; 2011 Nov; 12(10):620-31. PubMed ID: 21819530 [TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR; AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136 [TBL] [Abstract][Full Text] [Related]
6. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097 [TBL] [Abstract][Full Text] [Related]
7. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS; AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461 [TBL] [Abstract][Full Text] [Related]
8. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068 [TBL] [Abstract][Full Text] [Related]
9. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092 [TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894 [TBL] [Abstract][Full Text] [Related]
11. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D; Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
13. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP; Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J; HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116 [TBL] [Abstract][Full Text] [Related]
15. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301 [TBL] [Abstract][Full Text] [Related]
17. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D; J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785 [TBL] [Abstract][Full Text] [Related]
18. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. Hill A; Sawyer W HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663 [TBL] [Abstract][Full Text] [Related]
19. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D; AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]